Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Citeline Pharma Intelligence Awards Japan, now in its second year, will return to Tokyo on October 17, 2023, bringing together hundreds of leading innovators, to meet and network, discover new opportunities, and reflect on life-changing accomplishments made over the previous year.
The awards recognize outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market.
Categories cover the entire pharma and biotech lifecycle and include: Pharma Company of the Year, Best New Drug Award, Biotech Company of the Year, Best CRO/CDMO and Licensing Deal of the Year.
The Best New Drug Award recognizes excellence in pharmaceutical development. In this category, the judges will be looking for the small-molecule, biological, cell/gene therapy, digital therapeutic or vaccine product approved in Japan during the qualifying period that represents the best therapeutic advance in its area.
To enter this category, please answer the following:
Any recently launched new product is eligible to enter as long as it was approved in its first indication in Japan between 1 January 2022-30 June 2023. (Generic and biosimilar products are not eligible.)
Entrants must have played a key role in the development of the nominated product, for example as a sole licensee or co-developer responsible for clinical trials and/or regulatory submissions, and all company members of joint development or joint venture agreements should be disclosed in the application.
Designed to acknowledge excellence in leadership, the winner of this award will be the executive who has exhibited exemplary leadership throughout the qualifying period (1 January 2022-30 June 2023). Also important to the judges will be the executive’s career achievements, influence within the industry and characteristics that make a good leader, such as decisive and clear strategy, team building and employee welfare.
To enter this category, please answer the following:
Entrants must hold a C-suite executive position and be employed by the company at the time of nomination.
This award honors outstanding achievements by biotech companies over the qualifying period (1 January 2022-30 June 2023).
To enter this category, please answer the following:
This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.
This Award is to recognize contract research organizations or contract development and manufacturing organizations that provide full or specialist services to their clients and which have an office or other base (but not necessarily a head office) either in Japan or the Asia region, including Australia. Entrant companies must offer services in Japan, but the achievements listed in the entry form do not necessarily have to be trials or services/manufacturing conducted in Japan (for example, clinical trials conducted in China or Australia are also eligible).
Judging will consider the quality and benefits of services and relationships built with clients. For CROs, it will pay particular attention to innovative patient trial recruitment strategies brought to the table, while for CDMOs, novel, more efficient and/or lower cost production processes will be considered.
To enter this category, please answer the following:
To qualify, candidates must draw on their achievements in the qualifying period (1 January 2022-30 June 2023).
Deals considered here are those that involve the licensing of a particular drug, project or group of R&D assets from one company to another for further development and/ or marketing. (This category does not include more complex, broad partnerships between companies, for example to explore particular therapeutic strategies or mechanisms of action.)
The judges will look at all aspects from monetary and strategic value to the benefits they give to both sides.
To enter this category, please answer the following:
To qualify, licensing deals must have been closed during the qualifying period of (1 January 2022-30 June 2023).
This new Award seeks to reward successful and creative fundraising by pharma and biotech companies in Japan, which are either privately or publicly owned.
The basic criterion for this award is the total amount of money raised at one time – for example in a Series A (or later) funding round or through an IPO – but other factors should be considered as well. For example:
The investment can take various forms, including grants and public-private partnership deals, to fundraising from venture capital and private equity partners and initial public offerings. The majority of the new funds should be earmarked for use in drug discovery and/or company development. The qualifying period is 1 January 2022-30 June 2023.
The Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies over the qualifying period of 1 January 2022-30 June 2023. This special award is chosen not by the independent judging panel but by our own senior editorial team, based on a variety of key metrics as below:
You can nominate your own company but there is no shortlist and the winner is decided by our senior editorial team.
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their distinguished career in the biotech or pharmaceutical arena, primarily within industry.
All entry forms must include:
We welcome nominees for consideration for this Award but the decision lies not with the independent judging panel but with our senior editorial team. The winner may be retired or semi-retired but will still be active in the industry in some capacity.
Any entry form should outline, in no more than 1,500 words, what the nominee has accomplished during his or her career and say why they are worthy of this Award.
Steve Engen
Kazumi Fujikawa
Dr Shoichiro Hamano
Dr Keiji Hirai
Thomas Jonsson
Dr Shingo Kano
Aya Kubota
Mitsuru Miyata
Dr Toshio Miyata
Dr Mamoru Narukawa
Fumiyoshi Sakai
Dr Hiroyuki Sakamaki
Dr Noboru Yamamoto
Steve brings over 20 years of senior executive level operating and transaction experience in the biopharmaceutical industry, with expertise in Japanese/Asian markets. In 2014, he established his own biopharma consultancy, and continues to support Japanese, Chinese, and western biopharma clients. From 2014 until May 2018, Steve was Managing Director and Head of Asia for Locust Walk, where he established the Locust Walk Japan office. During the four years that Steve ran the Locust Walk Japan office, he oversaw eleven transactions (including buy-side and sell-side transactions) between western and Asian companies.
Steve previously headed the Japanese operations of Shire Pharmaceuticals. Before Shire, Steve served as CEO of Solasia Pharma, a cancer-focused development stage company. Raising over $40MM in venture capital, he built a portfolio of novel cancer drugs and established operations in Japan and China. Steve launched his biopharma career at Purdue Pharma in business development, and then held the position of President of Mundipharma Japan for nine years. In this role, he oversaw the development and commercialization of the company’s leading pain management franchise.
Steve, his wife, and two daughters currently have their primary residence in Bellevue, Washington. Steve is fluent in written and spoken Japanese.
Kazumi Fujikawa is well known in the “insight professional circle” for her distinguished experience that includes global, regional and local roles for various multinational corporation: Takeda, Pfizer, IQVIA and Sanofi. She is active promoting the values of Insight roles (Market Research, Competitive Intelligence and Forecasting etc.) by establishing HMIC (Healthcare Market Intelligence Community) and worked together with the network of Insight society in Europe and US. She is also active for the regional revitalization project of her birth place: Innoshima, Onomichi city.
She holds BA of English Literature, Notre Dame Seishin University, Japan and holds MBA, Marketing from Leicester University, UK. She is certified in leadership and organizational development from New York University. She is a certified MBTI instructor and National Licensed Career Consultant.
She is currently working as a corporate advisor of Seed Planning, the representative of HMIC and the representative of Ryu no Senaka (Innoshima Revitalization Project)
He is a recipient of the U.S. FDA Commissioner's Special Award and a former ICHGMP EWG member and received his PhD from the University of Tokyo and his Master's degree from Kanazawa University, in pharmacy, a registered Pharmacist, involved in new business development, technology transfer, licensing, negotiation, contract drafting, JV establishment, and M&A for 25 years in big pharma.
His areas of expertise include licensing, technology transfer, new business development, start-up consulting and related services, currently serves as an adviser to the Toyama Pharmaceutical Association. He also served as the Senior Vice President of KUTLO-NITT (TLO Union), as CD of Hokuriku Innovation Cluster for Health Science and adviser to the DBJ VC "BHP".
He has visited more than 250 venture companies in the world and made business contacts with more than 350 leading pharmaceutical companies in Japan and overseas. Traveled overseas more than 300 times.
Office is located in Nihonbashi, Tokyo, the center of Japan's pharmaceutical industry.
Dr Keiji Hirai joined KYORIN Pharmaceutical Co., Ltd. in April 1972. He was appointed Executive Director, Discovery Research Headquarters of KYORIN Pharmaceutical Co., Ltd. in 2002 and Director of ActivX Biosciences, Inc. (SanDiego) from 2004 to 2012. In 2009, he became the Representative Director and President & CEO, R&D Headquarters and Business Development of KYORIN Pharmaceutical Co., Ltd. and Executive Director of KYORIN Co., Ltd. In 2013, he was appointed Advisor of KYORIN Pharmaceutical Co., Ltd.
Dr Hirai is currently the Director (Outside) of Fuji Pharma Co., Ltd., Program Officer, Department of Research Promotion Division of Infectious Disease Research of Japan Agency for Medical Research and Development (AMED), Committee member (Department of CiCLE Innovation) of AMED, and a Visiting Professor, the Omura Satoshi Memorial Institute, Kitasato University.
He received his Ph. D. from Gunma University (School of Medicine) in May 1987.
Thomas established Zinagi, a lifescience consulting company, in 2013 and has successfully supported innovative medical device, medical software, and biotech companies. Thomas previously served as Lifescience Ambassador for Medicon Valley Alliance and prior to that held commercial positions at several global big pharma companies.
Shingo Kano is a Professor in Bio-Innovation Policy Unit, Graduate school of Frontier Science, the University of Tokyo, where he also completed his PhD in Science Policy. He had a varied career in industry as management consultant in Nomura Research Institute, securities analyst and venture capitalist for the healthcare sector in Nomura Securities and run the university spin off drug discovery firm as president and CEO for ten years before starting his academic career.
His current research focuses on the recognition gap between university and industry, the role and management of university spin off, how regulation and innovation interact in the advanced industries, and the changing role of universities and companies in the national innovation systems.
In 2002, graduated from the Faculty of Agriculture, Tokyo University of Agriculture and Technology, and joined Nikkei Business Publications. For seven years, starting in 2002, Kubota collected information and wrote articles about the bio- and healthcare industry inside and outside Japan as a reporter for a monthly magazine, Nikkei Biotechnology & Business (now discontinued), and a newsletter, Nikkei Biotech . In 2009 and after, Kubota collected information and wrote articles about end-of-life care, novel influenza, the Great East Japan Earthquake, and other topics as a reporter for Nikkei Medical, which is a magazine for physicians. Since 2014, Kubota has served as deputy editor of Nikkei Biotechnology & Business and deputy editor of Nikkei Medical. Since April 2023, Kubota has been in her current position and conducts research and writes articles focusing on the diversification of modalities in the pharmaceutical industry.
Mr. Miyata joined Nikkei Inc. in 1979 after completing a postgraduate degree in Botany at the University of Tokyo. Mr. Miyata then worked in the editorial department of Nikkei medical and was involved in the launch of Nikkei biotech. Mr. Miyata was then appointed as the Editor-in-Chief of Nikkei biotech in 1985. In July 2015, Mr. Miyata founded the Miyata Institute of Technologies and became the President. Then in April 2017, he founded Healthcare Innovation and was appointed it’s President.
He is also involved in various public activities such as being the Ministry of Health, Labour and Welfare and AMED.
In 1999, Miyata transferred into the Faculty of Medicine, Osaka University, in the third year, following his assignment to a laboratory related to medical-engineering cooperation at the School of Science and Engineering, Waseda University. In 2003, he joined the First Surgery Department of Osaka University. In 2009, Miyata faced issues related to drug lag and device lag on the medical front as a physician, joined the Ministry of Health, Labour and Welfare, and was involved in many healthcare reforms to establish rules for the practical use of pharmaceutical products, medical devices, and regenerative medicine.
He was engaged in restoration and recovery from the Great East Japan Earthquake as well. Miyata is still a working surgeon and regularly performs operations. At the same time, he is also promoting the establishment of community-based integrated care systems. To promote homecare, Miyata founded the MIH Clinic. Miyata engages in the protection of community healthcare, as well as company health management, and is active in the prevention of the deterioration of lifestyle-related diseases, and in home healthcare, daycare for sick children, online medical care, and COVID-19 measures.
Miyata is familiar with drug administration, as he was also in charge of the Investigational Committee for Usage of Unapproved/Off-label Drugs, advanced medical care, and measures against drug-induced damage while he was in the Ministry of Health, Labour and Welfare. Miyata engages in multifaceted activities to respond to the needs of the times, for example, by establishing a self-medication digital business in which physicians collaborate with pharmacists using a smartphone-based application.
In Miyata's laboratory of Waseda University, he is studying healthcare policy, regulatory science, online medical care/software/SaMD, healthcare/medical care DX, including the use of PHR and data, clinical research, clinical epidemiology, clinical study, PMD Acts, regenerative medicine system, medical insurance system, clinical examination, foods with function claims, etc. Moreover, Miyata promotes the development of human resources for clinical epidemiology as the Board member of the Society for Clinical Epidemiology.
Dr. Mamoru Narukawa graduated from the Tokyo University, Faculty of Pharmaceutical Sciences, and joined the New Drugs Division, Ministry of Health and Welfare in 1991. Since then he has experienced several posts concerning new drug review/approval, pharmaceutical regulation and policy reforms, and medical insurance system including drug pricing. He became an Associate Professor in the Division of Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences in 2007, and assumed the position of the Professor in 2016. His specialties are clinical trials, pharmaceutical regulations, and biostatistics.
After graduating from Arizona State University with a degree in Finance, Mr. Sakai joined Imperial Chemical Industries Japan, a British chemical company, where he worked for five years in Japan and the UK. Mr. Sakai then joined the Corporate Research Department of the Economic Research Institute of Yamaichi Securities. After this, Mr. Sakai joined Société Générale, working within Domestic Equities and the Corporate Research Department in 1998. Since 2002, he has worked as an analyst for the pharmaceutical industry in Deutsche Securities' Equities Research Department. Mr. Sakai joined Credit Suisse First Boston Securities (now Credit Suisse Securities (Japan) Limited) in July 2005 where he worked as a Senior Analyst and Director in the Equity Research Department. In both 2008 and 2009, Mr. Sakai was ranked third in the pharmaceutical sector by Institutional Investor magazine. He is a member of the Securities Analysis Association of Japan. He is also the author of several books.
Dr Hiroyuki Sakamaki is the professor for Graduate School of Health Innovation, Kanagawa University of Human Services. He taught at many schools around Japan, including Keio University, Meijo University, and Tokyo University of Science. He was also the chief research scientist for the Institute for Health Economics and Policy (IHEP) that is a non-profit organization established by the Ministry of Health, Labour and Welfare (MHLW). He is an expert for the health technology assessment in Japan holding an MBA and a doctorate degree in medical science. He conducts cost effectiveness analyses related to medical technologies in order to develop useful efficacy indicators.
Additionally, he specializes in research on pharmaceutical industry policies where he analyzes reimbursement of medicines and medical devices from a health economics perspective, and investigates environmental factors surrounding pharmaceutical and device companies. He has acted as chief researcher on several projects relating to advanced therapies such as biologics and has led research on generics and biosimilar use.
He is an active member of various health policy committees established by the MHLW. He works research projects related to pharmaceutical policy, most of the researches are used as the basis for the discussion of healthcare system reforms.
Dr. Yamamoto graduated from Hiroshima University School of Medicine in 1991 and started his residency in internal medicine at the National Cancer Center Hospital in 1995. Dr. Yamamoto became a physician in the Department of Respiratory Medicine at the National Cancer Center Hospital in 2000, and in 2013 he progressed to Director of the Department of Advanced Medicine there. Since 2019, Dr Yamamoto has worked as the Director of the Division of Clinical Research Support and Deputy Director of the National Cancer Center Hospital. Dr Yamamoto specializes in the early clinical development of novel anticancer agents, thoracic oncology and clinical pharmacology. Dr. Yamamoto received the ASCO Merit Award in 1996, 1999 and 2000, and has been a member of the editorial board of the Japanese Journal of Clinical Oncology since 2005.
Read the criteria for each category from the drop-down categories above. Then click ‘Begin Entry’ against the category/ies you wish to enter. Complete the downloadable entry form and once completed, email this to the awards team before the entry deadline of Monday, July 10, 2023.
Sponsorship provides a wealth of opportunities, from thought leadership to brand awareness and lead generation. Find out more about the numerous sponsorship opportunities available.
Sponsor Opportunities
Looking to attend the Citeline Pharma Intelligence Awards Japan? Book your table today for the awards!
BOOK YOUR TABLE
ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.
CMIC stands for Current Medical Information Center. In 1992, Dr. Kazuo Nakamura founded CMIC as the first Contract Research Organization (CRO) in Japan. CMIC Group is currently the largest clinical CRO in Japan, providing comprehensive services in drug development, clinical trial and clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge your drug development and manufacturing needs between the US and Japan. CMIC Group has over 7,000 employees and 25 sites globally.
EPS Holdings, Inc. is a healthcare solutions provider that has been handling all processes from drug discovery and development to sales, marketing, consulting, and various other solutions since its founding as a pioneer CRO in Japan in 1991.
In recent years, EPS Holdings, Inc. has been providing comprehensive solutions to pharmaceutical and medical device companies, medical institutions, and academia through our efforts in Big Data & AI, regenerative medicine, and other areas including SMO (Site Management Organization) and CSO (Contract Sales Organization). In 2021, EPS Holdings, Inc. launched an innovative medicine business and started services to support the clinical development of seeds originating at academic institutions and domestic and global biotech ventures and to support marketing in and outside Japan.
Today, the EPS Group has over 35 group companies and continues to evolve day by day with more than 7,800 employees. For more information, please visit our website.
About Syneos Health – Long Form (122 words)
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit Syneos Health | Biopharma Solutions Organization & CRO or subscribe to our podcast.
Syneos Health | Biopharma Solutions Organization & CRO
The Syneos Health Podcast
The Citeline Pharma Intelligence Awards Japan are now in their second year of recognizing outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market. Take a look back at our previous Awards and winners.
Yes, if you meet the entry criteria, you are welcome to enter more than one category. Please submit an entry form for each category you wish to enter.
Yes, there is a section on the entry form for them to do so.
Yes, you can. However, you cannot enter a category in which you are sponsoring. For more details on sponsorship, please see the Sponsorship Guide.
Please feel free to contact the Japanese Award Management Team (inquiry.jp@informa.com). If necessary, we will contact the judging committee for a response.
After submitting your entry form, the Award Management Team will send you an email confirming receipt.
